Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc. reported a significant 76% year-over-year increase in revenue for Q3 FY25, primarily driven by the contributions from its Sleep Center Network (SCN), which suggests the effectiveness of their new model in accelerating market adoption and revenue growth without substantial additional investment. Service revenue more than doubled in this period to $4.6 million, highlighting robust demand particularly for sleep testing and treatment-center services, while projections indicate continued revenue growth as the company expands its Special Operations (SO) teams. Additionally, the company's clinical results demonstrate high efficacy, with significant improvements in patients with moderate to severe obstructive sleep apnea, further enhancing its market position as awareness of sleep disorders rises, especially in the fast-growing Asia Pacific region.

Bears say

Vivos Therapeutics Inc. is experiencing a negative financial outlook primarily due to a 9% year-over-year decline in total revenue for the first half of 2025, attributed to a transition from their legacy business model to a new direct sleep center management channel. Despite a quarterly revenue increase of 27% from Q1 to Q2 FY25, sales remain below projections, and gross margins have decreased to 55% due to discounting and alterations in the product and service mix. The company faces multiple risks, including projected sales growth challenges, difficulties in capital acquisition for operational expansion, and a longstanding history of operating losses, which contribute to an uncertain path toward achieving sustained profitability.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.